IV vs Oral: Evidence Based Antibiotic Use-Slides

Pdf Summary

This presentation by James Soo Kim addresses the evolving role of intravenous (IV) versus oral (PO) antibiotic therapy in treating bacteremia, infective endocarditis (IE), and osteomyelitis (OM). Traditionally, IV treatment has been favored due to historical concerns about oral drug absorption and efficacy, particularly stemming from early penicillin use data. However, recent evidence challenges this dogma, showing that oral step-down therapy can be effective and safe in appropriate patients, potentially reducing hospital length of stay, costs, and complications related to IV access such as PICC line-associated infections, thrombosis, and patient discomfort.<br /><br />Key points include:<br /><br />1. Historical Context: IV therapy became standard based on early 20th-century data citing poor oral penicillin bioavailability and treatment failures. Advances in antibiotic pharmacology and clinical trials now support oral regimens for select infections.<br /><br />2. Clinical Evidence:<br />   - Multiple randomized controlled trials (RCTs) and systematic reviews demonstrate no significant differences in treatment failure, mortality, or adverse events between IV and PO therapies for gram-negative bacteremia, IE caused by select organisms (e.g., Streptococcus, Enterococcus, MSSA), and osteomyelitis.<br />   - The POET trial and subsequent follow-ups showed non-inferiority and even improved long-term outcomes with partial oral therapy in IE.<br />   - Osteomyelitis studies, including those involving diabetic foot infections and prosthetic joint infections, support step-down oral therapy following initial IV treatment.<br /><br />3. Candidate Selection: Patients suitable for oral therapy generally are hemodynamically stable, afebrile, have a controlled source of infection, and infections caused by organisms susceptible to antibiotics with high oral bioavailability.<br /><br />4. Antibiotics with high oral bioavailability include fluoroquinolones (except ciprofloxacin to some extent), linezolid, TMP/SMX, doxycycline, and certain β-lactams like amoxicillin.<br /><br />5. Infectious disease consultation improves outcomes by optimizing antimicrobial selection and management.<br /><br />In conclusion, while IV therapy remains important for unstable patients or those with severe infections or resistant organisms, increasing evidence supports oral step-down therapy in selected cases, balancing efficacy with reduced risks and costs. Clinicians are encouraged to use clinical judgment and evidence-based criteria when considering oral therapy for bacteremia, IE, and osteomyelitis.

Meta Tag

Concept Intravenous Antibiotic Therapy

Concept Oral Antibiotic Therapy

Concept Bacteremia

Concept Infective Endocarditis

Concept Osteomyelitis

Keywords

intravenous antibiotic therapy

oral antibiotic therapy

bacteremia treatment

infective endocarditis

osteomyelitis management

oral step-down therapy

antibiotic bioavailability

PICC line complications

randomized controlled trials

infectious disease consultation

Intravenous Antibiotic Therapy

Oral Antibiotic Therapy

Bacteremia

Infective Endocarditis

Osteomyelitis